170 related articles for article (PubMed ID: 16893995)
1. Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity.
Michon F; Uitz C; Sarkar A; D'Ambra AJ; Laude-Sharp M; Moore S; Fusco PC
Clin Vaccine Immunol; 2006 Aug; 13(8):936-43. PubMed ID: 16893995
[TBL] [Abstract][Full Text] [Related]
2. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
Wessels MR; Paoletti LC; Kasper DL; DiFabio JL; Michon F; Holme K; Jennings HJ
J Clin Invest; 1990 Nov; 86(5):1428-33. PubMed ID: 2243123
[TBL] [Abstract][Full Text] [Related]
4. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
Paoletti LC; Wessels MR; Rodewald AK; Shroff AA; Jennings HJ; Kasper DL
Infect Immun; 1994 Aug; 62(8):3236-43. PubMed ID: 8039893
[TBL] [Abstract][Full Text] [Related]
5. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.
Paoletti LC; Kasper DL; Michon F; DiFabio J; Jennings HJ; Tosteson TD; Wessels MR
J Clin Invest; 1992 Jan; 89(1):203-9. PubMed ID: 1729272
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Wessels MR; Paoletti LC; Pinel J; Kasper DL
J Infect Dis; 1995 Apr; 171(4):879-84. PubMed ID: 7706814
[TBL] [Abstract][Full Text] [Related]
7. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
[TBL] [Abstract][Full Text] [Related]
8. Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine.
Paoletti LC; Wessels MR; Michon F; DiFabio J; Jennings HJ; Kasper DL
Infect Immun; 1992 Oct; 60(10):4009-14. PubMed ID: 1398913
[TBL] [Abstract][Full Text] [Related]
9. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
[TBL] [Abstract][Full Text] [Related]
10. Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy.
Wessels MR; Paoletti LC; Guttormsen HK; Michon F; D'Ambra AJ; Kasper DL
Infect Immun; 1998 May; 66(5):2186-92. PubMed ID: 9573106
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of Haemophilus influenzae type b conjugate vaccine prepared using different polysaccharide chain lengths.
Rana R; Dalal J; Singh D; Kumar N; Hanif S; Joshi N; Chhikara MK
Vaccine; 2015 May; 33(23):2646-54. PubMed ID: 25907408
[TBL] [Abstract][Full Text] [Related]
12. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women.
Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Carey VJ; Hickman ME; Kasper DL
J Infect Dis; 2000 Oct; 182(4):1129-38. PubMed ID: 10979909
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
[TBL] [Abstract][Full Text] [Related]
14. Anti-Group B Streptococcus Glycan-Conjugate Vaccines Using Pilus Protein GBS80 As Carrier and Antigen: Comparing Lysine and Tyrosine-directed Conjugation.
Nilo A; Morelli L; Passalacqua I; Brogioni B; Allan M; Carboni F; Pezzicoli A; Zerbini F; Maione D; Fabbrini M; Romano MR; Hu QY; Margarit I; Berti F; Adamo R
ACS Chem Biol; 2015 Jul; 10(7):1737-46. PubMed ID: 25906283
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.
Wessels MR; Paoletti LC; Rodewald AK; Michon F; DiFabio J; Jennings HJ; Kasper DL
Infect Immun; 1993 Nov; 61(11):4760-6. PubMed ID: 8406875
[TBL] [Abstract][Full Text] [Related]
16. An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus.
Paoletti LC; Kasper DL; Michon F; DiFabio J; Holme K; Jennings HJ; Wessels MR
J Biol Chem; 1990 Oct; 265(30):18278-83. PubMed ID: 2120228
[TBL] [Abstract][Full Text] [Related]
17. Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.
Yang HH; Madoff LC; Guttormsen HK; Liu YD; Paoletti LC
Infect Immun; 2007 Jul; 75(7):3455-61. PubMed ID: 17470542
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of conjugated group B streptococcal type Ia vaccine in a rabbit model of ascending infection.
Davies JK; Paoletti LC; McDuffie RS; Madoff LC; Lee S; Eskens J; Gibbs RS
Am J Obstet Gynecol; 1999 Oct; 181(4):803-8. PubMed ID: 10521733
[TBL] [Abstract][Full Text] [Related]
19. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old.
Palazzi DL; Rench MA; Edwards MS; Baker CJ
J Infect Dis; 2004 Aug; 190(3):558-64. PubMed ID: 15243932
[TBL] [Abstract][Full Text] [Related]
20. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.
Baker CJ; Rench MA; Paoletti LC; Edwards MS
Vaccine; 2007 Jan; 25(1):55-63. PubMed ID: 16919857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
